Cantargia reports updated encouraging survival data from CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer
Cantargia AB today announced updated interim results from the CANFOUR phase I/IIa clinical trial investigating nadunolimab in first line therapy of pancreatic cancer (PDAC) in combination with chemotherapy. The updated dataset from the initial 33 patients eligible for efficacy analysis continue to show stronger results than expected from chemotherapy only. Median survival is 12.7 months, median immune progression-free survival (iPFS) is 7.2 months, and 1-year survival rate is 55%. At the time of analysis, 12 patients were still alive and two patients were on therapy. Safety and response rates